Cellular 'Computers' Gain a Hard Drive
By Brendan Borrell,
Nature News
| 11. 14. 2014
Untitled Document
A new DNA-based recorder allows bioengineers to create cell cultures that detect information in their environment and store it for later use. Such 'designer' cells might in the future be used to monitor water quality in a village, or measure the amount of sugar a person eats. The technique is described this week in Science1.
In synthetic biology, genes are engineered to regulate each other's expression in such a way that they can perform logic operations similar to those in computer circuits. Memory storage has long been considered one of the key components needed to fulfil the promise of this technology.
“Building gene circuits requires not only computation and logic, but a way to store that information,” says bioengineer Timothy Lu of the Massachusetts Institute of Technology in Cambridge. “DNA provides a very stable form of memory and will allow us to do more complex computing tasks.”
In previous synthetic-biology attempts, data storage has been laborious to create. It also recorded only the presence or absence of one particular sensory input, and could be used...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
